Compare General Dynamics Corporation (GD) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Dynamics Corporation vs TG Therapeutics Inc — how do they compare? General Dynamics Corporation trades at $331.13 (market cap $89.26B), while TG Therapeutics Inc trades at $54.88 (market cap $8.16B). The key difference: General Dynamics Corporation is far larger — about 10.9× TG Therapeutics Inc's market cap, and General Dynamics Corporation pays a 1.93% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold General Dynamics Corporation for 85 Days and TG Therapeutics Inc for 16 Days on average.
| GD | TGTX | |
|---|---|---|
Market Cap | $89.26B | $8.16B |
Volume | 1,496,273 | 1,735,121 |
Sector | Industrials | Health |
52-Week High | $395.97 | $59.06 |
52-Week Low | $312.53 | $26.94 |
Typical Hold Time | 85 Days | 16 Days |
Enterprise Value | $94.40B | $8.37B |
Dividend Yield | 1.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Dynamics (GD) trades at $331.77, up 1.57% today, with a bearish technical signal but strong fundamental performance. Recent quarters have consistently beaten EPS estimates, with Q3 2026 expected at $4.14. Revenue grew to $52.55B in 2025, and net income margin improved to 8.18%. Analyst consensus is bullish with a $420.57 price target, supported by defense budget tailwinds and dividend stability.
The outlook remains positive due to robust Pentagon spending and contract visibility, though technical weakness near support at $320 poses short-term risk. Long-term growth is underpinned by submarine and vehicle demand, but investors face volatility from defense budget cycles and geopolitical uncertainties. The stock offers value with a P/E of 20.12 and a sustainable dividend.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
